arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

IONIS PHARMACEUTICALS INC

IONS
$56.55 ▲ +2.10 (+3.86%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

IONIS PHARMACEUTICALS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $9.0B
Dividend Yield
Revenue Growth 33.8%
Op. Margin -40.4%
ROIC -16.7%
FCF / Share $-2.00
Trailing P/E
Price / Book 18.9x
FCF Yield
Debt / Equity 3.71
info Valuation on last close. End-of-day price, Aug 7, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$943.71M
↑ +33.8%
Net Income Profit after all expenses
$-381.39M
↑ +16.0%
Operating Margin Operating profit as % of sales
-40.4%
↑ +40.0% 6th
FCF / Share Free cash flow per share
$-2.00
↑ +45.3%
Long-Term Debt Long-term obligations
$1.81B
↑ +44.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
6
Returns
11
Financial Health
15
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 72 quarters